Colostrinin, and uses thereof
The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system.
1. A method of treating a human patient afflicted with dementia comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.
2. The method according to claim 1 wherein the Colostrinin is non-ovine Colostrinin.
3. The method according to claim 1 , wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.
4. The method according to claim 1 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.
5. The method according to claim 4 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
6. The method according to claim 4 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.
7. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.
8. The method according to claim 7 , wherein the Colostrinin is non-ovine Colostrinin.
9. The method according to claim 7 , wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.
10. The method according to claim 7 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.
11. The method according to claim 10 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
12. The method according to claim 10 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.
13. A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.
14. The method according to claim 13 wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient.
15. The method according to claim 14 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
16. The method according to claim 15 wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once.
17. The method according to claim 13 wherein the Colostrinin is formulated for oral administration.
18. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.
19. The method according to claim 18 wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient.
20. The method according to claim 19 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
21. The method according to claim 20 wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once.
22. The method according to claim 18 wherein the Colostrinin is formulated for oral administration.
23. A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms.
24. The method according to claim 23 wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient.
25. The method according to claim 24 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
26. The method according to claim 25 wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once.
27. The method according to claim 23 wherein the nonapeptide is formulated for oral administration.
28. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms.
29. The method according to claim 28 wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient.
30. The method according to claim 29 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.
31. The method according to claim 30 wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once.
32. The method according to claim 28 wherein the nonapeptide is formulated for oral administration.